Erratum to: ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients (High Blood Pressure and Cardiovascular Prevention DOI: 10.1007/s40292-014-0043-6);ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients

High Blood Pressure and Cardiovascular Prevention

Volumn 21, Issue 2, 2014, Pages 137-147

  Volpe, Massimo ^a,b   De La Sierra, Alejandro ^c   Kreutz, Reinhold ^d   Laurent, Stéphane ^e   Manolis, Athanasios J ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f IASO GENERAL HOSPITAL   (Greece)

Author keywords

Amlodipine; Cardiovascular disease; Cerebrovascular disease; Chronic kidney disease; Fixed dose combination; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; Risk factors

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; CALCIUM ANTAGONIST; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NITRENDIPINE; OLMESARTAN; RAMIPRIL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; DRUG COMBINATION; IMIDAZOLE DERIVATIVE; TABLET; TETRAZOLE DERIVATIVE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; JOB EXPERIENCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MEDICATION COMPLIANCE; METABOLIC SYNDROME X; MICROALBUMINURIA; ORGAN INJURY; PILL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; RISK FACTOR; SYSTOLIC HYPERTENSION; TRANSIENT ISCHEMIC ATTACK; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TABLET; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MEDICATION ADHERENCE; RISK FACTORS; TABLETS; TETRAZOLES; TREATMENT OUTCOME;

EID: 84904679335     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-014-0049-0     Document Type: Erratum

References (73)

1. Lawes CM, Vander Hoorn S, Rodgers A, et al. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513-8. (Pubitemid 351626187)
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903- 13. (Pubitemid 35472129)
3. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-52.
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;19(338):b1665.
5. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929-40.
6. Banegas JR, López-García E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32(17):2143-52.
7. Corrao G, Parodi A, Nicotra F, et al. Better compliance to anti-hypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610-8.
8. Faria C, Wenzel M, Lee KW, et al. A narrative review of clinical inertia: focus on hypertension. J Am Soc Hypertens. 2009;3(4):267-76.
9. Frieden TR, King SM, Wright JS. Protocol-based treatment of hypertension: a critical step on the pathway to progress. JAMA. 2013. doi:10.1001/jama.2013. 282615.
10. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357.
11. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699-705.
12. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32(20):2499-506.
13. Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124(2):128-35.
14. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-9. (Pubitemid 47176510)
15. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
16. Byrd JB, Zeng C, Tavel HM, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J. 2011;162(2):340-6.
17. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124-31.
18. Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J. 2011;32(22):2851-906.
19. Verbeke F, Lindley E, Van Bortel L, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. Nephrol Dial Transpl. 2013. doi:10.1093/ndt/gft321.
20. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
21. Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31(19):2369-429.
22. Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. doi:10.1093/ eurheartj/eht296.
23. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507.
24. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33(14):1787-847.
25. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201-7. (Pubitemid 46111014)
26. Tocci G, Paneni F, Palano F, et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens. 2011;24(5):582-90.
27. Noto H, Goto A, Tsujimoto T, et al. Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Me7tab Syndr Obes. 2013;26(6):257-61.
28. Omboni S, Malacco E, Mallion JM, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials. Drugs Aging. 2012;29(12):981-92.
29. Teramoto T, Kawamori R, Miyazaki S, et al. Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study. Hypertens Res. 2012;35(12):1136-44.
30. Hsueh WA, Shojaee A, Maa JF, et al. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Curr Med Res Opin. 2012;28(11):1809-18.
31. Zhang Y, Zhang X, Liu L, et al. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32(12):1500-8.
32. Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ. 2011;4(344):d7541.
33. Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29(5):528-42.
34. Sander GE, Giles TD. What is the blood pressure goal for the elder patient 75 years of age or older? Curr Cardiol Rep. 2011;13(6):485-91.
35. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens. 2007;25(10):2168-77. (Pubitemid 47476316)
36. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875-86. (Pubitemid 36677151)
37. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens. 2004;22(8):1605-12. (Pubitemid 39037613)
38. Malacco E, Omboni S, Volpe M, Auteri A, Zanchetti A, ESPORT Study Group. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens. 2010;28(11):2342-50.
39. Zanchetti A, Bond MG, Hennig M, et al. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2004;22(6):1201-12. (Pubitemid 38721012)
40. Zanchetti A, Rosei EA, Dal Palù C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of longterm randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998;16(11):1667-76. (Pubitemid 28515494)
41. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25.
42. Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54(5):1084-91.
43. Schneider MP, Hua TA, Böhm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55(21):2299-307.
44. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-9. (Pubitemid 40282586)
45. Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296(10):1242-8. (Pubitemid 44394895)
46. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48. (Pubitemid 351688350)
47. Lv J, Perkovic V, Foote CV, et al. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2012;12:CD004136.
48. Bakris GL, Sowers JR, Glies TD, et al. Treatment of hypertension in patients with diabetes-an update. J Am Soc Hypertens. 2010;4(2):62-7.
49. Patel A; ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40.
50. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29(7):1253-69.
51. Menne J, Izzo JL Jr, Ito S, et al. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens. 2012;30(4):811-8.
52. Chrysant SG, Izzo JL Jr, Kereiakes DJ, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012;6(2):132-41.
53. Ram CV, Sachson R, Littlejohn T, et al. Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Am J Cardiol. 2011;107(9):1346-52.
54. Nesbitt SD, Shojaee A, Maa JF, et al. Efficacy of an amlodipine/ olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BPCRUSH study). J Hum Hypertens. 2013;27(7):445-52.
55. Disertori M, Lombardi F, Barlera S, et al. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. Am Heart J. 2011;162(2):382-9.
56. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens. 2012;30(2):239-52.
57. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013;185(11):949-57.
58. Blacklock CL, Hirst JA, Taylor KS, et al. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis. Diabet Med. 2011;28(10):1182-7.
59. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173-81.
60. Volpe M, Tocci G, Sciarretta S, et al. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens. 2009;27(5):941-6.
61. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke. 1997;28(12):2557-62. (Pubitemid 28007667)
62. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-35. (Pubitemid 37410190)
63. Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35(4):1024.
64. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34(11):2741-8. (Pubitemid 37392777)
65. Xu J, Zhao X, Wang Y, et al. Impact of a better persistence with antihypertensive agents on ischemic stroke outcomes for secondary prevention. PLoS One. 2013;8(6):e65233.
66. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens. 2008;26(7):1477-86.
67. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011;171(5):384-94.
68. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450-6.
69. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575-81. (Pubitemid 30240501)
70. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;16(346):f55.
71. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28(4):457-62. (Pubitemid 47343566)
72. Raphael CE, Whinnett ZI, Davies JE, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009;95(1):56-62.
73. National Institute for Health and Clinical Excellence.Hypertension: the clinical management of primary hypertension in adults. London 2011. http://www.nice.org.uk/guidance/CG127/Guidance. Accessed October 2013.